Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Synlogic, Inc.

$0.66

+0.04 (+7.27%)

D 31Pipeline Score Fair Value Biotech · Clinical
Market Cap
6.55 M
EPS
-0.27
P/E Ratio
-
Value Trade
457.25
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    -

  • R&D Expenses

    49.00 K

  • Operating CF

    -563.00 K

  • Total Assets

    14.61 M

  • Total Liabilities

    14.61 M

  • Equity

    12.55 M

  • D/E Ratio

    12,345

-50.88 %
Week
-52.14 %
1 Month
-67.91 %
3 Month
-65.54 %
6 Month
-99.03 %
5 Year
-99.93 %
All Time
Cash Data
Healthy

  • Cash Position

    14.11 M

  • Monthly Burn

    188.00 K

  • Runway

    73.9 mo

  • Burn Trend

    Decelerating

  • SEC Filing

    May 14, 2026
Overview
Volume
748.00
52 Week Range
0.56 - 1.96
% held by Insiders
39.35 %
% held by Institutions
37.16 %
Enterprise Value
-9.04 M
Total Shares
11.71 M
Short %
0.05 %
Float Shares
7.04 M
Company Description
Founded:30-09-2015

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D31
Pipeline Score
$13M
Pipeline Value
Fair Value
Valuation Signal
6
Drugs Scored
2.0x
rNPV / MCap
Top 38%
Micro Cap
(rank 562 of 905)
Percentile Rank
Synlogic, Inc. faces pipeline headwinds (31/100), with $258M risk-adjusted pipeline value, led by SYNB1934 in Healthy (Phase 1).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
SYNB1934
Small molecule		HealthyPhase 1NCT049845257% $70M COMPLETED 106 - -Dec 10, 2021 -May 18, 2022
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in SYBX
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
SYBX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SYBX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SYBX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
SYBX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
SYBX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How SYBX ranks across every disease it competes in
Competitive Position is a premium feature
See how SYBX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial